Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Tutt

Showing results (11-20 of 91) with videos related to

Pageof 10
Sort By:
Future Oncology (London, England)|April 9, 2010
PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancersJustin Stebbing, Paul Ellis, Andrew Tutt
Cancer Journal (Sudbury, Mass.)|December 14, 2021
New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast CancerElizabeth Harvey-Jones, Gemma Vinas Villaro, Andrew Tutt
BMJ (Clinical Research Ed.)|January 1, 2009
Adjuvant radiotherapy for breast cancerCrispin Hiley, Andrew Tutt, Mylin Torres, et al.
Lancet (London, England)|December 13, 2016
Molecular alterations in triple-negative breast cancer-the road to new treatment strategiesCarsten Denkert, Cornelia Liedtke, Andrew Tutt, et al.
Cancer Discovery|May 16, 2012
Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancersJudith Balmaña, Susan M Domchek, Andrew Tutt, et al.
Breast Care (Basel, Switzerland)|August 2, 2013
Profiling the immune stromal interface in breast cancer and its potential for clinical impactSheeba Irshad, Anita Grigoriadis, Katherine Lawler, et al.
Journal of Vascular and Interventional Radiology : JVIR|March 28, 2023
Next-Generation Sequencing and Image-Guided Tissue Sampling: A Primer for Interventional RadiologistsJason Yeung, Nicos Fotiadis, Athanasios Diamantopoulos, et al.
European Journal of Cancer (Oxford, England : 1990)|June 11, 2011
Risk factors for metachronous contralateral breast cancer suggest two aetiological pathwaysVoralak Vichapat, Cheryl Gillett, Ian S Fentiman, et al.
Plos One|July 30, 2010
Comparative Membranome expression analysis in primary tumors and derived cell linesPaolo Uva, Armin Lahm, Andrea Sbardellati, et al.
Pathology|July 1, 2022
The increasing importance of pathology in modern clinical trial conduct: OlympiA as a case in pointLauren Kalinowski, Giuseppe Viale, Susan Domchek, et al.
Pageof 10

Showing results (11-20 of 91) with videos related to

Sort By:
Pageof 10
Future Oncology (London, England)|April 9, 2010
PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancersJustin Stebbing, Paul Ellis, Andrew Tutt
Cancer Journal (Sudbury, Mass.)|December 14, 2021
New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast CancerElizabeth Harvey-Jones, Gemma Vinas Villaro, Andrew Tutt
BMJ (Clinical Research Ed.)|January 1, 2009
Adjuvant radiotherapy for breast cancerCrispin Hiley, Andrew Tutt, Mylin Torres, et al.
Lancet (London, England)|December 13, 2016
Molecular alterations in triple-negative breast cancer-the road to new treatment strategiesCarsten Denkert, Cornelia Liedtke, Andrew Tutt, et al.
Cancer Discovery|May 16, 2012
Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancersJudith Balmaña, Susan M Domchek, Andrew Tutt, et al.
Breast Care (Basel, Switzerland)|August 2, 2013
Profiling the immune stromal interface in breast cancer and its potential for clinical impactSheeba Irshad, Anita Grigoriadis, Katherine Lawler, et al.
Journal of Vascular and Interventional Radiology : JVIR|March 28, 2023
Next-Generation Sequencing and Image-Guided Tissue Sampling: A Primer for Interventional RadiologistsJason Yeung, Nicos Fotiadis, Athanasios Diamantopoulos, et al.
European Journal of Cancer (Oxford, England : 1990)|June 11, 2011
Risk factors for metachronous contralateral breast cancer suggest two aetiological pathwaysVoralak Vichapat, Cheryl Gillett, Ian S Fentiman, et al.
Plos One|July 30, 2010
Comparative Membranome expression analysis in primary tumors and derived cell linesPaolo Uva, Armin Lahm, Andrea Sbardellati, et al.
Pathology|July 1, 2022
The increasing importance of pathology in modern clinical trial conduct: OlympiA as a case in pointLauren Kalinowski, Giuseppe Viale, Susan Domchek, et al.
Pageof 10